Premium
Addition of plerixafor for CD 34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation
Author(s) -
Hauge Anne Werner,
Haastrup Eva Kannik,
Sengeløv Henrik,
Minulescu Lia,
Dickmeiss Ebbe,
FischerNielsen Anne
Publication year - 2014
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.12383
Subject(s) - plerixafor , medicine , mobilization , transplantation , regimen , adjuvant , granulocyte colony stimulating factor , stem cell , cd34 , surgery , haematopoiesis , hematopoietic stem cell transplantation , oncology , chemotherapy , cxcr4 , biology , genetics , chemokine , receptor , archaeology , history
Background I n allogeneic hematopoietic stem cell ( HSC ) transplantation, collection of a sufficient number of HSCs at a fixed time point is crucial. For HSC mobilization into the peripheral blood, the standard regimen, that is, granulocyte–colony‐stimulating factor ( G ‐ CSF ), may be inadequate. Use of plerixafor as adjuvant to G ‐ CSF is so far off‐label in healthy donors. Study Design and Methods We present six cases in which the “just‐in‐time” addition of plerixafor ensured proper CD 34+ collection from healthy donors with insufficient G ‐ CSF mobilization. In four of these cases a high number of CD 34+ cells was needed due to subsequent CD 34+ selection or haploidentical transplantation. Results From all six donors a sufficient number of CD 34+ cells was obtained by using plerixafor as an adjuvant to G ‐ CSF . This treatment regimen resulted in only mild side effects for the donor. Conclusion We have presented six cases with different causes leading to insufficient G ‐ CSF mobilization in allogeneic donors and in which the administration of plerixafor just‐in‐time ensured a proper graft for transplantation.